Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Inventory (2016 - 2025)

Historic Inventory for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $2.9 million.

  • Cumberland Pharmaceuticals' Inventory fell 3492.38% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 3492.38%. This contributed to the annual value of $4.0 million for FY2024, which is 1322.02% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Inventory of $2.9 million as of Q3 2025, which was down 3492.38% from $3.2 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Inventory high stood at $10.9 million for Q2 2023, and its period low was $2.9 million during Q3 2025.
  • Its 5-year average for Inventory is $7.4 million, with a median of $8.7 million in 2023.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Inventory surged by 3247.49% in 2021, and later plummeted by 6063.32% in 2024.
  • Cumberland Pharmaceuticals' Inventory (Quarter) stood at $8.4 million in 2021, then increased by 17.01% to $9.9 million in 2022, then crashed by 53.27% to $4.6 million in 2023, then dropped by 13.22% to $4.0 million in 2024, then fell by 26.63% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.2 million for Q2 2025, and $4.1 million during Q1 2025.